CASI Pharmaceuticals, Inc. · OTC:CASIF
CASI Pharmaceuticals — Investor Presentation (June 2018)
13 slides from CASI Pharmaceuticals's investor presentation, Jun 4, 2018
Slide 1: CASI Pharmaceuticals
VW CASI Pharmaceuticals NASDAQ: CASI June 2018
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward- looking statemen
Slide 3: CASI Pharmaceuticals
CASI Pharmaceuticals CASI (NASDAQ: CASI) is a U.S. biopharmaceutical company focused on the acquisition, development, and commercialization of high quality, innovative therapeutics addressing cancer and other unmet medical needs, with a focus on China and the U.S. Corporate Headquarters in Maryland,
Slide 4: Company Overview
Company Overview • Management: Experienced team with accomplished track record in North America and China • Diversified product portfolio: ― In-licensed from Spectrum Pharmaceuticals EVOMELA® (CE-Melphalan), MARQIBO® (vinCRIStine sulfate LIPOSOME), ZEVALIN® (ibritumomab tiuxetan) ― Acquired from San
Slide 5: Bi-Cultural Board, Management Team & Advisors
Bi-Cultural Board, Management Team & Advisors BOARD OF DIRECTORS Dr. Wei-Wu He, Executive Chairman IDG-ACCEL China Fund Venture Partner; Managing Director, ETP Global Fund, L.P.; Chairman & CEO, OriGene Technologies, Inc. Dr. Quan Zhou Founder, Managing Director and General Partner at IDG Capital Pa
Slide 6: Business Strategy
Business Strategy Bringing Innovative and High Quality Medicines to 1.5 Billion People in China while Addressing the U.S. and Global Markets Cost-Effectively • Large patient population in China seeking innovative and high quality medicines • Recent China FDA (CFDA) reforms allow for expedited approv
Slide 7: Historic Harmonization of China Regulatory Environment
Historic Harmonization of China Regulatory Environment Historic challenges: • Issues with comparative quality (international standards vs local products & manufacturers) • Longer timeframe for review & new drug approval • Lack of capacity in regulatory bodies / application backlog China State Counci
Slide 8: Historic Harmonization of China Regulatory Environment
Historic Harmonization of China Regulatory Environment Recent Reforms & Implications: • Shortened IND / NDA review timelines: Increased number of reviewers at CDE to resolve current backlog; goal is for review timelines to be ~six months by YE2018 with zero backlog • Priority reviews: Target approva
Slide 9: Diversified Product Portfolio
Diversified Product Portfolio Through Acquisitions, In-licensing and Internally Developed Innovative, Targeted Oncology Therapeutics and High Quality ANDAs Greater China Rights US FDA ANDAs Acquired From SPPI ENMD-2076, Global Rights Acquired From Sandoz •25 FDA Approved ANDAs Innovative Drug Candid
Slide 10: Licensed Products
Licensed Products • CASI entered into licensing agreement with Spectrum Pharmaceuticals (Nasdaq: SPPI) for China development & commercialization of hematological oncology products • Exclusive rights to three commercial products (China Territories): ― EVOMELA® Conditioning treatment prior to autologo
Slide 11: Acquired 29 ANDA Products & Pipeline
Acquired 29 ANDA Products & Pipeline 25 FDA Approved, 4 Pending FDA Approval ANDAs Diverse Portfolio Across Attractive Key Products Indication Therapeutic Area Entecavir HBV Infection 12% Ondansetron CINV 35% 19% Methimazole Hyperthyroidism 15% 8% Repaglinide Diabetes 11% Bisoprolol Fumarate Hyperte
Slide 12: CASI's Partnership Approach & Goals
CASI’s Partnership Approach & Goals • Leverage CASI’s development, regulatory, and commercial infrastructure in China • Rapidly reach clinical milestone inflection points and registrations cost-effectively • Accelerate product commercialization and life-cycle management Strategic Innovative, Partner
Slide 13: CASI Pharmaceuticals
VW CASI Pharmaceuticals
CASI Pharmaceuticals — Investor Presentation (June 2018) on 6ix